251 related articles for article (PubMed ID: 26802148)
21. Emerging treatment options for B-cell lymphomas.
Zelenetz AD
J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):666-9. PubMed ID: 25995425
[TBL] [Abstract][Full Text] [Related]
22. Integrating understanding of epidemiology and genomics in B-cell non-Hodgkin lymphoma as a pathway to novel management strategies.
Glass S; Phan A; Williams JN; Flowers CR; Koff JL
Discov Med; 2016 Mar; 21(115):181-8. PubMed ID: 27115168
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
24. Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab.
Ku M; Chong G; Hawkes EA
Blood Rev; 2017 Jan; 31(1):23-35. PubMed ID: 27568879
[TBL] [Abstract][Full Text] [Related]
25. Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
Barth MJ; Minard-Colin V
Br J Haematol; 2019 Jun; 185(6):1111-1124. PubMed ID: 30701541
[TBL] [Abstract][Full Text] [Related]
26. Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
Sujobert P; Rioufol C; Salles GA
Cancer J; 2016; 22(1):12-6. PubMed ID: 26841011
[TBL] [Abstract][Full Text] [Related]
27. Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.
Makita S; Hosoba R; Tobinai K
Expert Opin Drug Saf; 2020 Sep; 19(9):1105-1120. PubMed ID: 32715803
[TBL] [Abstract][Full Text] [Related]
28. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract][Full Text] [Related]
29. New drugs for the treatment of non-Hodgkin lymphomas.
Smith SM
Chin Clin Oncol; 2015 Mar; 4(1):14. PubMed ID: 25841721
[TBL] [Abstract][Full Text] [Related]
30. Management of Patients with MYC-Altered Lymphomas.
Landsburg DJ
Curr Hematol Malig Rep; 2016 Jun; 11(3):208-17. PubMed ID: 26983958
[TBL] [Abstract][Full Text] [Related]
31. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
32. Innovative strategies in lymphoma therapy.
Jäger U
Wien Klin Wochenschr; 2003 Aug; 115(13-14):462-70. PubMed ID: 13677264
[TBL] [Abstract][Full Text] [Related]
33. Ofatumumab in the treatment of non-Hodgkin's lymphomas.
Karlin L; Coiffier B
Expert Opin Biol Ther; 2015 Jul; 15(7):1085-91. PubMed ID: 26043777
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma.
Feuring-Buske M; Buske C; Unterhalt M; Hiddemann W
Ann Hematol; 2000 Apr; 79(4):167-74. PubMed ID: 10834503
[TBL] [Abstract][Full Text] [Related]
35. Human Bcl-2 antisense therapy for lymphomas.
Cotter FE; Waters J; Cunningham D
Biochim Biophys Acta; 1999 Dec; 1489(1):97-106. PubMed ID: 10807000
[No Abstract] [Full Text] [Related]
36. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
Czuczman MS; Grillo-López AJ; White CA; Saleh M; Gordon L; LoBuglio AF; Jonas C; Klippenstein D; Dallaire B; Varns C
J Clin Oncol; 1999 Jan; 17(1):268-76. PubMed ID: 10458242
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
Ansell SM; Geyer SM; Maurer MJ; Kurtin PJ; Micallef IN; Stella P; Etzell P; Novak AJ; Erlichman C; Witzig TE
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6056-63. PubMed ID: 17062681
[TBL] [Abstract][Full Text] [Related]
38. Current and ongoing clinical development of immunotherapy in B-cell malignancies. Proceedings of a conference. January 2001, Kailua-Kona, Hawaii, USA.
Semin Oncol; 2002 Feb; 29(1 Suppl 2):1-112; quiz 113-21. PubMed ID: 11876162
[No Abstract] [Full Text] [Related]
39. New developments in extracutaneous lymphomas.
Chott A; Raderer M
Semin Cutan Med Surg; 2000 Jun; 19(2):149-56. PubMed ID: 10892718
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
